SSRIs for Teenagers With Depression or Anxiety

Home > Depression > SSRIs for Teenagers

Fluoxetine combined with cognitive behavioral therapy produced a response in 71.0% of depressed adolescents over 12 weeks in the Treatment for Adolescents With Depression Study, compared with 60.6% for fluoxetine alone, 43.2% for CBT alone, and 34.8% for placebo (March and colleagues, JAMA, 2004). The trial enrolled 439 adolescents aged 12 to 17 at 13 US sites between 2000 and 2003, and it remains the central reference for medication decisions in teenage depression.

Parents arrive at this question carrying the boxed warning, and they should. Across 24 placebo-controlled pediatric trials pooled by the FDA, antidepressants were associated with a 2 percentage point higher rate of suicidal thinking or behavior than placebo, with no completed suicides in any trial (Hammad and colleagues, Archives of General Psychiatry, 2006). As a double board-certified child and adolescent psychiatrist, I make the decision to start an SSRI with both sets of numbers on the table at once.

Only a few SSRIs carry pediatric approvals, and the list is narrower than most parents expect

Pediatric approval requires placebo-controlled trials in that age group, and most SSRIs never completed them for depression. The current labels:

• Fluoxetine (Prozac): major depressive disorder at ages 8 to 18, and obsessive-compulsive disorder at ages 7 to 17.
• Escitalopram (Lexapro): major depressive disorder from age 12, and generalized anxiety disorder from age 7.
• Sertraline (Zoloft): obsessive-compulsive disorder at ages 6 to 17 only. Two pediatric depression trials did not support an indication, and it carries no pediatric anxiety approval despite being the drug tested in the largest pediatric anxiety trial.
• Fluvoxamine: obsessive-compulsive disorder at ages 8 to 17.
• Duloxetine (Cymbalta), an SNRI: generalized anxiety disorder at ages 7 to 17.

Accordingly, much of what child psychiatrists prescribe for anxiety is off-label, including sertraline for separation and social anxiety. Off-label here means the manufacturer never filed for the indication, although the trials exist. The 2020 AACAP guideline states that both CBT and SSRIs have considerable empirical support for pediatric anxiety, with SNRIs holding some support (Walter and colleagues, JAACAP, 2020).

In adolescent depression, fluoxetine is the best-supported drug and the combination with CBT is the best-supported treatment

TADS randomized 439 adolescents to fluoxetine 10 to 40 mg daily, CBT, both, or placebo for 12 weeks. Notably, 29% of the sample had clinically significant suicidal thinking at baseline, and it improved in all four groups, most in the combination arm (March and colleagues, JAMA, 2004). Seven of 439 patients (1.6%) attempted suicide during the acute phase; none died.

The 36-week follow-up matters for parents. By week 36, response rates were 86% for combination treatment, 81% for fluoxetine alone, and 81% for CBT alone, so the gap closed with time. However, suicidal events over 36 weeks were more common with fluoxetine alone (14.7%) than with combination treatment (8.4%) or CBT alone (6.3%), and the authors concluded that adding CBT to medication enhances its safety (March and colleagues, Archives of General Psychiatry, 2007).

A network meta-analysis of 34 trials, 5,260 young people, and 14 antidepressants found that only fluoxetine was statistically more effective than placebo (standardized mean difference -0.51), with evidence quality rated very low in most comparisons (Cipriani and colleagues, Lancet, 2016). In children under 12, only fluoxetine showed benefit in age-stratified analyses (Bridge and colleagues, JAMA, 2007). Accordingly, I usually start a depressed teenager on fluoxetine or escitalopram and pair it with CBT whenever the family can arrange it; the CBT page and the medication versus therapy comparison cover sequencing.

In pediatric anxiety, the medication effect is larger and the combination with CBT is larger still

The Child/Adolescent Anxiety Multimodal Study (CAMS) randomized 488 children aged 7 to 17 with separation anxiety disorder, generalized anxiety disorder, or social phobia to 14 sessions of CBT, sertraline up to 200 mg daily, both, or placebo for 12 weeks. Response rates were 80.7% for the combination, 59.7% for CBT, 54.9% for sertraline, and 23.7% for placebo (Walkup and colleagues, New England Journal of Medicine, 2008). Adverse events, including suicidal and homicidal ideation, were no more frequent with sertraline than with placebo, and no child attempted suicide.

Across indications, the pediatric antidepressant effect is strongest in anxiety. Pooled risk differences for response versus placebo were 37.1% for non-OCD anxiety disorders, 19.8% for OCD, and 11.0% for depression, corresponding to numbers needed to treat of 3, 6, and 10 (Bridge and colleagues, JAMA, 2007). In other words, three anxious children need treatment for one to respond because of the drug, versus ten depressed adolescents. For a teenager whose generalized anxiety or social anxiety has stalled school and friendships, an SSRI plus CBT is the evidence-supported first step (see the anxiety treatment page).

The boxed warning measured suicidal thinking and behavior in trials, and no trial recorded a suicide

In 2004 the FDA required a boxed warning on all antidepressants for pediatric patients. The underlying analysis pooled 24 placebo-controlled trials with 4,582 patients across depression, OCD, anxiety, and ADHD. The risk ratio for suicidal ideation or behavior was 1.66 for SSRIs in depression trials and 1.95 for all drugs across all indications, and the overall risk difference was 0.02, about 2 additional cases per 100 treated (Hammad and colleagues, Archives of General Psychiatry, 2006). There were no completed suicides.

Current labels present the signal as 14 additional patients with suicidal thoughts or behaviors per 1,000 treated under age 18, 5 additional at ages 18 to 24, 1 fewer at ages 25 to 64, and 6 fewer at 65 and older. Whether the risk extends beyond roughly four months of treatment is unknown.

A second meta-analysis put benefit and risk on one scale. Across 27 trials, the pooled risk difference for suicidal ideation or attempt was 0.7%, a number needed to harm of 143, against numbers needed to treat of 10 for depression, 6 for OCD, and 3 for anxiety; within each indication the suicidality difference did not reach statistical significance (Bridge and colleagues, JAMA, 2007). Taken at face value, roughly 14 depressed adolescents respond because of the drug for every one who develops new suicidal thinking because of it, and the ratio is more favorable in anxiety.

After the warning, youth prescribing fell and suicide attempts rose; the data are observational

SSRI prescriptions for children and adolescents fell by approximately 22% in both the United States and the Netherlands after the warnings. US youth suicide rates rose 14% between 2003 and 2004, and Dutch youth suicide rates rose 49% between 2003 and 2005 (Gibbons and colleagues, American Journal of Psychiatry, 2007).

A quasi-experimental study of 11 US health plans, covering roughly 1.1 million adolescents and 1.4 million young adults from 2000 to 2010, found that antidepressant use fell 31.0% among adolescents and 24.3% among young adults in the second year after the warnings, while psychotropic drug poisonings, a validated proxy for suicide attempts, rose 21.7% and 33.7%. Completed suicides did not change (Lu and colleagues, BMJ, 2014).

These studies cannot establish causal relationships; the rise in poisonings may reflect untreated depression, changes in care-seeking, or other period effects. Yet the pattern is broadly consistent with the concern that a warning designed to protect adolescents likely reduced treatment for a condition that itself carries suicide risk. Declining treatment is also a decision with consequences.

How I monitor the first weeks

The labels instruct prescribers to monitor every antidepressant-treated patient closely for clinical worsening, suicidality, and unusual behavior, especially during the initial months and at dose changes, and to counsel families to watch and report. The AACAP practice parameter for depressive disorders builds on the same monitoring (Birmaher and colleagues, JAACAP, 2007). In practice:

• Before the first dose: screening for personal and family history of bipolar disorder, mania, or hypomania, which the labels require; baseline depression and anxiety rating scales; a written safety plan; and securing medications and other means at home.
• Starting dose: the fluoxetine label directs 10 or 20 mg daily for pediatric depression, with 10 mg as the starting and target dose in lower-weight children; the escitalopram label directs 10 mg daily, maximum 20 mg. I start at the low end. Dosing is individual and decided with the prescriber.
• The first four weeks: I see or speak with the teenager and a parent frequently, typically weekly, and ask directly about sleep, restlessness, irritability, and suicidal thoughts. Parents observe daily, as the fluoxetine label directs.
• Weeks four through twelve: rating scales are repeated, since TADS measured response at 12 weeks and CAMS at weeks 4, 8, and 12. A dose increase is considered after several weeks without sufficient improvement, the label's own language.
• Ongoing: height and weight for children on fluoxetine, and therapy alongside medication wherever possible.

This cadence is the routine of psychiatric medication management in this practice for adolescents and younger children.

Activation and manic switch are the reasons to call, and sometimes the reasons to stop

Activation is a cluster of impulsivity, restlessness, and insomnia that emerges early after an SSRI is started or increased, and its prevalence and risk factors remain poorly characterized (Luft and colleagues, Current Problems in Pediatric and Adolescent Health Care, 2018). The labels list the related symptoms: anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania. When activation appears, prescribers typically lower the dose or stop the medication, then reassess.

Manic switch is rarer and more consequential. In a claims analysis of 87,920 privately insured patients aged 5 to 29 treated for anxiety or non-bipolar mood disorders, 5.4% received a new bipolar diagnosis over a median 41 weeks; SSRI exposure was associated with a hazard ratio of 2.1, and the association was strongest at ages 10 to 14, with a number needed to harm of 10 versus 23 at ages 15 to 29 (Martin and colleagues, Archives of Pediatrics & Adolescent Medicine, 2004). These observational data cannot separate drug effect from the natural emergence of bipolar disorder in youth already at risk. They do justify the screening the labels require and a low threshold for stopping an SSRI when a teenager's sleep need collapses, speech speeds up, or mood turns expansive (see the bipolar disorder page).

Finally, the labels direct prescribers to consider changing the regimen, including discontinuation, when depression is persistently worse or suicidal thoughts emerge, and to reduce the dose gradually when stopping, whenever possible. The pace is the prescriber's call, made with the family.

How parents can ask about it

The question I hear most often is some version of this one: "If the medication can cause suicidal thoughts, why would we give it to a kid who already has them?" Depression is the stronger driver of those thoughts. In TADS, suicidal thinking fell in every treatment arm, including fluoxetine alone, and fell most when medication and CBT were combined. The monitoring above exists to catch the minority who worsen early.

Parents are entitled to ask any prescriber: which drug, and whether it is approved for the child's diagnosis and age; the starting dose and when it would change; how often the family will be seen in the first month and whom to call on a weekend; which changes to watch for at home; whether therapy is part of the plan; and when the medication would be stopped. If the answers are vague, a second opinion is reasonable before the first dose.

Who this practice fits, and when to go elsewhere

This fits families with an adolescent or child whose depression or anxiety has lasted more than a few weeks and is affecting school, sleep, or friendships, particularly when a pediatrician has suggested an SSRI and the family wants a child psychiatrist to decide and monitor. It also fits teenagers already on an SSRI who have had activation, no response, or an unclear diagnosis.

Some situations belong elsewhere. A teenager with active suicidal intent, a recent attempt, or psychotic symptoms needs an emergency department or crisis team today; outpatient care follows. A child under 7 with anxiety is generally treated with CBT and parent-based approaches first. Eating disorders with medical instability, and substance use that dominates the picture, need specialized programs alongside psychiatric care.

Cost and booking

Initial evaluations run 60 to 90 minutes and include time with the parent and with the teenager alone. The practice is out-of-network with all insurance plans. You pay directly and receive a superbill to submit for reimbursement; many NYC plans with out-of-network benefits reimburse a meaningful share once the deductible is met. Fees are laid out at fees and out-of-network costs, and the benefits check page explains what to ask your insurer first.

Bring school reports, prior evaluations, and a list of current and past medications with doses and dates. Schedule a consultation or call (646) 893-4309.

Related

Depression · Anxiety · Adolescent psychiatry · Child psychiatry · CBT · Medication vs therapy vs both · Medication management · Second opinions · Emotional blunting on antidepressants · Antidepressant sexual side effects · Antidepressants and weight gain · Depression with ADHD: combining medications · Anxiety medication options · How long antidepressants take to work · Lexapro vs Zoloft · Stopping antidepressants · Wellbutrin vs SSRIs

When Depression Becomes an Emergency

Adolescent depression carries suicide risk with or without medication, and the first weeks after starting or changing an SSRI are the time to watch most closely. Suicidal thoughts without immediate intent warrant a same-day call to the prescriber.

Frequently Asked Questions

Do SSRIs work for teenage depression?

Yes, with a modest effect that grows when therapy is added. In TADS (2004), 60.6% of adolescents responded to fluoxetine and 71.0% to fluoxetine plus CBT over 12 weeks, versus 34.8% on placebo. Across pediatric depression trials, the number needed to treat is about 10. Fluoxetine is the best-supported drug; a 2016 network meta-analysis found it was the only antidepressant clearly better than placebo.

Which SSRIs are FDA-approved for children and teenagers?

Fluoxetine is approved for depression from age 8 and OCD from age 7. Escitalopram is approved for depression from age 12 and generalized anxiety disorder from age 7. Sertraline is approved for pediatric OCD (ages 6 to 17) only, and fluvoxamine for pediatric OCD (ages 8 to 17). Duloxetine, an SNRI, is approved for generalized anxiety disorder at ages 7 to 17. Other uses, including sertraline for anxiety, are off-label and trial-supported.

What does the boxed warning on antidepressants actually mean?

It summarizes pooled placebo-controlled trials in which antidepressants were associated with more reports of suicidal thinking or behavior in patients under 25. Current labels put the difference at 14 additional patients per 1,000 treated under age 18. No pediatric trial recorded a completed suicide. The warning requires close monitoring in the first months and at dose changes, and the same labels carry pediatric approvals.

Is CBT alone enough, or does my teenager need medication?

For mild to moderate symptoms, CBT alone is a reasonable first step, and in TADS, CBT alone caught up to medication by week 36. For moderate to severe depression, medication produced a faster response, and the combination performed best at every time point. In pediatric anxiety (CAMS), 80.7% responded to the combination versus 55 to 60% for either treatment alone. Severity, duration, and access to skilled CBT drive the decision.

What side effects should parents watch for in the first weeks?

Activation is the most common early concern: new restlessness, impulsivity, irritability, trouble sleeping, or agitation. Rarer signals include a sharp drop in sleep need, rapid speech, or expansive mood, which raise concern for a manic switch and require a same-day call. New or worsening suicidal thoughts should be reported immediately. Stomach upset and headache are common and usually fade. Prescribers typically lower the dose or stop the drug when activation appears.

Did the 2004 warning reduce teen suicides?

The available data point the other way, though they are observational. After the warning, youth SSRI prescriptions fell about 22% in the US and the Netherlands, and US youth suicide rates rose 14% between 2003 and 2004. A study of 11 health plans found adolescent antidepressant use fell 31% while psychotropic drug poisonings, a proxy for attempts, rose 21.7%; completed suicides did not change. These associations cannot establish cause.

Sources

1. March J, Silva S, Petrycki S, et al; TADS Team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA. 2004;292(7):807–820. PMID 15315995
2. March JS, Silva S, Petrycki S, et al. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007;64(10):1132–1143. PMID 17909125
3. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–2766. PMID 18974308
4. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry. 2006;63(3):332–339. PMID 16520440
5. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–1696. PMID 17440145
6. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016;388(10047):881–890. PMID 27289172
7. Gibbons RD, Brown CH, Hur K, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry. 2007;164(9):1356–1363. PMID 17728420
8. Lu CY, Zhang F, Lakoma MD, et al. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014;348:g3596. PMID 24942789
9. Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med. 2004;158(8):773–780. PMID 15289250
10. Luft MJ, Lamy M, DelBello MP, McNamara RK, Strawn JR. Antidepressant-induced activation in children and adolescents: risk, recognition and management. Curr Probl Pediatr Adolesc Health Care. 2018;48(2):50–62. PMID 29358037
11. Birmaher B, Brent D; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1503–1526. PMID 18049300
12. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107–1124. PMID 32439401
13. Prozac (fluoxetine) prescribing information, revised 03/2017. FDA label
14. Lexapro (escitalopram) prescribing information, 2024. FDA label
15. Cymbalta (duloxetine) prescribing information, 2015. FDA label
16. Zoloft (sertraline) prescribing information. DailyMed
17. Fluvoxamine maleate tablets prescribing information. DailyMed